HOLX
NEUTRAL
$75.58
Live
Hologic, Inc. · NYSE
Target $76.67
(+1.4%)
$51.9
52W Range
$75.78
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 01, 2026
Market cap
$16.87B
P/E
31.36
ROE
10.9%
Profit margin
13.2%
Debt/Equity
0.48
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
HOLX shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Mixed signals with both opportunities and risks present.
Key Strengths
Low debt with D/E ratio of 0.48
Key Risks
High valuation with P/E of 31.4
Premium vs Graham Number ($35.71)
AI Fair Value Estimate
Based on comprehensive analysis
$16.87
-77.7% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
38
Weak
35
50
50
55
0
AI Verdict
HOLX shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Mixed signals with both opportunities and risks present.
Key drivers: Low debt with D/E ratio of 0.48, High valuation with P/E of 31.4, Premium vs Graham Number ($35.71)
Confidence
40%
Value
35/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
- Premium 31.4x trailing earnings multiple.
- Trades above Graham Number.
Future
50/100
Rule-based growth outlook.
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Past
50/100
Historical performance + price trend: Shares moved +1.7% over 5Y and +23.1% over 1Y.
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Health
55/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Low D/E ratio (0.48).
Watchpoints
No urgent risks highlighted.
Dividend
0/100
Dividend policy fallback.
Positives
- Insufficient data for clear positives.
Watchpoints
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$75.58
Analyst Target
$76.67
Upside/Downside
+1.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for HOLX and closest competitors.
Updated 2026-04-01
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
HOLX
Hologic, Inc.
Primary
|
+1.7% | -6.2% | +23.1% | +12.7% | +0.2% | +0.1% |
|
GMAB
Genmab A/S
Peer
|
-15.8% | -27.2% | +50.2% | -11.2% | +1.1% | +2.8% |
|
ZBH
Zimmer Biomet Holdings, Inc.
Peer
|
-38.9% | -27.0% | -18.2% | -7.5% | -8.3% | +4.1% |
|
BBIO
BridgeBio Pharma, Inc.
Peer
|
+18.4% | +720.5% | +110.0% | +68.2% | +1.8% | +2.1% |
|
ILMN
Illumina, Inc.
Peer
|
-67.1% | -45.5% | +55.4% | +29.8% | -7.2% | -2.2% |
HOL
Hologic, Inc.
Primary
5Y
+1.7%
3Y
-6.2%
1Y
+23.1%
6M
+12.7%
1M
+0.2%
1W
+0.1%
GMA
Genmab A/S
Peer
5Y
-15.8%
3Y
-27.2%
1Y
+50.2%
6M
-11.2%
1M
+1.1%
1W
+2.8%
ZBH
Zimmer Biomet Holdings, Inc.
Peer
5Y
-38.9%
3Y
-27.0%
1Y
-18.2%
6M
-7.5%
1M
-8.3%
1W
+4.1%
BBI
BridgeBio Pharma, Inc.
Peer
5Y
+18.4%
3Y
+720.5%
1Y
+110.0%
6M
+68.2%
1M
+1.8%
1W
+2.1%
ILM
Illumina, Inc.
Peer
5Y
-67.1%
3Y
-45.5%
1Y
+55.4%
6M
+29.8%
1M
-7.2%
1W
-2.2%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
31.36
Forward P/E
15.58
PEG Ratio
N/A
P/B Ratio
3.21
P/S Ratio
4.09
EV/Revenue
4.13
EV/EBITDA
12.61
Market Cap
$16.87B
Profitability
Profit margins and return metrics
Profit Margin
13.18%
Operating Margin
22.99%
Gross Margin
60.38%
ROE
10.86%
ROA
7.43%
Growth
Revenue and earnings growth rates
Revenue Growth
+2.5%
Earnings Growth
-9.2%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
-10.9%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.48
Low debt
Current Ratio
4.04
Strong
Quick Ratio
3.1
Excellent
Cash/Share
$10.6
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$1.0B
Gross Margin
56.0%
Op. Margin
23.0%
Net Margin
17.1%
Total Assets
$9.2B
Liabilities
$3.9B
Equity
$5.2B
Debt/Equity
0.75x
Operating CF
$0.2B
CapEx
$-0.0B
Free Cash Flow
$0.2B
FCF Yield
85%
Healthcare Sector Comparison
Comparing HOLX against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
31.36
This Stock
vs
75.44
Sector Avg
-58.4%
(Discount)
Return on Equity (ROE)
10.86%
This Stock
vs
-88.14%
Sector Avg
-112.3%
(Below Avg)
Profit Margin
13.18%
This Stock
vs
-16.28%
Sector Avg
-180.9%
(Weaker)
Debt to Equity
0.48
This Stock
vs
2.66
Sector Avg
-81.9%
(Less Debt)
Revenue Growth
2.5%
This Stock
vs
124.04%
Sector Avg
-98.0%
(Slower)
Current Ratio
4.04
This Stock
vs
4.47
Sector Avg
-9.7%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
HOLX
Hologic, Inc.
|
NEUTRAL | $16.87B | 31.36 | 10.9% | 13.2% | $75.58 | |
|
GMAB
Genmab A/S
|
NEUTRAL | $17.46B | 18.36 | 17.5% | 25.9% | $28.28 | Compare |
|
ZBH
Zimmer Biomet Holdings, Inc.
|
NEUTRAL | $18.03B | 25.63 | 5.6% | 8.6% | $90.97 | Compare |
|
BBIO
BridgeBio Pharma, Inc.
|
BEARISH | $14.92B | - | -% | -225.3% | $77.87 | Compare |
|
ILMN
Illumina, Inc.
|
NEUTRAL | $18.85B | 22.62 | 33.4% | 19.6% | $123.26 | Compare |
HOLX
Hologic, Inc.
NEUTRAL
Mkt Cap
$16.9B
P/E
31.4
ROE
10.9%
Price
$75.58
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-26 | DOCKENDORFF CHARLES J | Director | Stock Award | 3,190 | - |
| 2026-02-26 | MCBRIDE-WENDELL AMY A. | Director | Stock Award | 3,190 | - |
| 2026-02-26 | MADAUS MARTIN D PH.D. | Director | Stock Award | 3,190 | - |
| 2026-02-26 | MCMILLAN WAYDE D | Director | Stock Award | 3,190 | - |
| 2026-02-26 | STEWART STACEY D | Director | Stock Award | 3,190 | - |
| 2026-02-26 | HANTSON LUDWIG N | Director | Stock Award | 3,190 | - |
| 2026-02-26 | STAMOULIS CHRISTIANA | Director | Stock Award | 3,190 | - |
| 2026-02-26 | MOHTASHAMI NANAZ | Director | Stock Award | 3,190 | - |
| 2025-11-10 | OBERTON KARLEEN MARIE | Chief Financial Officer | Stock Award | 43,741 | - |
| 2025-11-10 | MACMILLAN STEPHEN P | Chief Executive Officer | Stock Award | 169,582 | - |
| 2025-11-10 | HORVATH MARK | Officer | Stock Award | 13,458 | - |
| 2025-11-10 | LIDDY ANNE M | General Counsel | Stock Award | 17,496 | - |
| 2025-11-10 | COHN BENJAMIN JORDAN | Officer | Stock Award | 5,047 | - |
| 2025-11-10 | VERSTREKEN JAN | Officer | Stock Award | 16,823 | - |
| 2025-11-10 | MITCHELL ESSEX D | Chief Operating Officer | Stock Award | 47,106 | - |
DOCKENDORFF CHARLES J
Director
2026-02-26
3,190 shares
MCBRIDE-WENDELL AMY A.
Director
2026-02-26
3,190 shares
MADAUS MARTIN D PH.D.
Director
2026-02-26
3,190 shares
MCMILLAN WAYDE D
Director
2026-02-26
3,190 shares
STEWART STACEY D
Director
2026-02-26
3,190 shares
HANTSON LUDWIG N
Director
2026-02-26
3,190 shares
STAMOULIS CHRISTIANA
Director
2026-02-26
3,190 shares
MOHTASHAMI NANAZ
Director
2026-02-26
3,190 shares
OBERTON KARLEEN MARIE
Chief Financial Officer
2025-11-10
43,741 shares
MACMILLAN STEPHEN P
Chief Executive Officer
2025-11-10
169,582 shares
HORVATH MARK
Officer
2025-11-10
13,458 shares
LIDDY ANNE M
General Counsel
2025-11-10
17,496 shares
COHN BENJAMIN JORDAN
Officer
2025-11-10
5,047 shares
VERSTREKEN JAN
Officer
2025-11-10
16,823 shares
MITCHELL ESSEX D
Chief Operating Officer
2025-11-10
47,106 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
HOLD
9 analysts
Argus Research
2026-01-12
Buy
Hold
Evercore ISI Group
2026-01-05
Outperform
In-Line
Morgan Stanley
2025-11-11
Equal-Weight
Equal-Weight
Mizuho
2025-10-23
Outperform
Neutral
Raymond James
2025-10-22
Outperform
Market Perform
Stephens & Co.
2025-10-22
Overweight
Equal-Weight
JP Morgan
2025-10-22
Overweight
Neutral
Leerink Partners
2025-10-21
Market Perform
Market Perform
BTIG
2025-10-21
Neutral
Neutral
Needham
2025-10-21
Hold
Hold
Past News Coverage
Recent headlines mentioning HOLX from our newsroom.
Newest → oldest
No matching news yet.